Background {#Sec1}
==========

The *FTO* rs9939609 gene variant has been consistently associated with BMI and obesity, however clear population differences have been identified \[[@CR1]\]. Despite the high prevalence of obesity in Mexico, the *FTO* risk allele is considerably less frequent, both in admixed and Native populations as compared to Europeans (0.21, 0.06 and 0.46, respectively). Interestingly, rs9939609 has been associated only with class III obesity, but not with overall obesity or BMI in admixed Mexican adults \[[@CR2], [@CR3]\], and rs1421085, in high linkage disequilibrium with rs9939609, was not associated with obesity or BMI in admixed Mexican children \[[@CR4]\]. It has been stated that loci that are specific to a single ancestry might contribute to genetic susceptibility across populations \[[@CR5]\]. The *ABCA1-*R230C variant (rs9282541) is an ancestry-specific polymorphism private to the Americas and has been strongly associated with low HDL-cholesterol (HDL-C), although its association with BMI and obesity is inconsistent \[[@CR6]--[@CR8]\]. This allele is of particular interest, because it is relatively frequent in the Mexican mestizo population (0.11), is functional and was found to interact with BMI affecting abdominal fat distribution particularly in Mexican premenopausal women \[[@CR8]\]. The aim of this study was to analyze possible *FTO* rs9939609 - *ABCA1* rs9282541 interactions affecting BMI, waist circumference (WC) and HDL-C levels in individuals from Central Mexico, which could help explain the differences observed between this and European populations.

Methods {#Sec2}
=======

Study population description {#Sec3}
----------------------------

The studied population included 3938 DNA samples of unrelated Mexican mestizo adults from 4 different cohorts and 636 DNA samples of unrelated school-aged children. All cohorts include samples from Central Mexico and have been previously described (Table [1](#Tab1){ref-type="table"}). Protocols for each cohort were approved by their respective Institutional Ethics Committee. Fully informed written consent for participation was attained from all participants or legal guardians.Table 1Description of the study cohortsStudy (Reference)Sample size (% ancestry^a^)Region (State)Males (%)Mean age (years ± SD)Mean BMI (Kg/m^2^ ± SD)Mean WC (cm ± SD)Mean HDL-C (mg/dL ± SD)Romero-Hidalgo et al. \[[@CR16]\]525 (67.5)Central Mexico (Mexico City, Hidalgo, Edo. De México, Morelos, Querétaro)31.2%46.2 ± 13.627.7 ± 4.592.0 ± 14.144.8 ± 12.7Velázquez-Cruz et al. \[[@CR17]\]1207 (50.6)Central Mexico (Morelos)30.3%50.9 ± 15.327.0 ± 4.593.7 ± 10.844.3 ± 11.4Villarreal-Molina et al. \[[@CR8]\]1511 (72.5)Central Mexico (Mexico City)50.9%53.1 ± 9.328.4 ± 4.394.8 ± 11.645.9 ± 13.3Villalobos-Comparán et al. \[[@CR2]\]695 (67.5)Central Mexico (Mexico City)36.0%40.0 ± 13.627.2 ± 5.289.1 ± 13.446.3 ± 12.5León-Mimila et al. \[[@CR3]\]636Central Mexico (Mexico City)48.23%9.4 ± 1.8520.0 ± 3.8470.2 ± 11.346.8 ± 10.9^a^Proportion of individuals with an ancestry estimation

Genotyping {#Sec4}
----------

The *FTO* rs9939609 and *ABCA1* rs9282541 variants were genotyped in 3938 DNA samples using TaqMan assays (ABI Prism 7900HT Sequence Detection System, Applied Biosystems). In addition, because the Mexican-Mestizo population is admixed, individual ancestry estimates were analyzed for 2354 individuals to test whether the results could be confounded by population stratification. Different panels of ancestry informative markers were used for each cohort (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Expression analysis {#Sec5}
-------------------

*FTO* and *ABCA1* mRNA expression was measured in subcutaneous (SAT) and visceral (VAT) adipose tissue biopsies from 22 admixed Mexican patients (16 female and 6 male), aged 25 to 55 years with BMI \> =40 kg/m^2^, who underwent bariatric surgery at the Hospital General Rubén Leñero in Mexico City. Total RNA was extracted with RNeasy Lipid Tissue Mini Kit (Qiagen), cDNA was reverse transcribed with TaqMan Reverse Transcription Reagents Kit (Applied Biosystems). Expression was analyzed using GeneChip Human Genome 2.0 ST Array (Affymetrix). *FTO* and *ABCA1* expression were validated by Real-Time PCR (LightCycler 480 II, Roche), using the following primers and probes: ctcggagaattagtttaggatatttca (forward) tctgacccccaaagatgatg (reverse) and probe \#59 for *FTO*, and tgctgcatagtcttgggactc (forward), acctcctgtcgcatgtcact (reverse) and probe \#17 for *ABCA1*. Hypoxanthine phosphoribosyl transferase (*HPRT*) expression was measured as reference \[[@CR2]\].

Statistical methods {#Sec6}
-------------------

HDL-C measurements were log-transformed for the analysis. Generalized linear regression (GLM) models were used to evaluate the individual effect of each single nucleotide variant and the interaction between *FTO* and *ABCA1* risk variants, adjusting for age, gender, ancestry and BMI as appropriate. GLM models were also used to compare mean values of subcutaneous and visceral *FTO* gene expression, adjusted for age and gender. Thus a model with main effects for risk variants and the adjusted variables plus the interactions between risk variants was fitted. All statistical analyses were performed using SPSS v.15.

Results {#Sec7}
=======

*FTO* and *ABCA1* risk allele frequencies were 20.3 and 10.0% in the overall population, respectively. In order to avoid potential population stratification, all individuals included in the analysis were from Central Mexico.

In the overall analysis and under additive inheritance models, the *FTO* "A" risk allele was not significantly associated with higher BMI (β = 0.187, *P* = 0.143) or higher WC (β = 0.409, *P* = 0.208), nor was the *ABCA1* "T" risk allele associated with BMI or WC (β = 0.247, *P* = 0.154 and β = 0.369, *P* = 0.403, respectively). Furthermore, although HDL-C levels were higher in *FTO* "A" homozygous individuals, the association did not reach statistical significance (β = 0.005, *P* = 0.097). As expected, the *ABCA1* "T" allele was strongly associated with lower HDL-C levels (β = −0.03, *P* = 2.37 × 10^−12^) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Association of *FTO* rs9939609 and *ABCA1* rs9282541 risk variants, independently and stratified, with BMI, waist circumference (WC) and HDL-cholesterol (HDL-C) levels, adjusting for age, gender and BMI as appropriate

In order to assess a possible *FTO-ABCA1* gene interaction, we sought associations between the *FTO* risk variant and BMI, WC and HDL-C, stratified by the absence or presence of the *ABCA1* risk allele ("CC" and "CT/TT" genotypes, respectively). Interestingly, in the absence of the *ABCA1* risk "T" allele, the *FTO* risk variant was significantly associated with higher BMI (β = 0.284, *P* = 0.042, *n* = 3191) and marginally associated with higher WC (β = 0.650, *P* = 0.063, *n* = 3191). In contrast, in the presence of the *ABCA1* risk allele, the *FTO* risk variant was not associated with BMI (*P* = 0.421, *n* = 747) or WC (*P* = 0.376, *n* = 747). The interaction analyses between *FTO* rs9939609 and *ABCA1* rs9282541 affecting BMI and WC were statistically significant (*P* = 0.040 and *P* = 0.045, respectively). *ABCA1* and *FTO* gene variants showed no significant interaction affecting HDL-C levels (*P* = 0.856) (Fig. [1](#Fig1){ref-type="fig"}).

Individual ancestry estimates were available in 60% of the samples. After adjusting for Native American ancestry, the statistical significance of interactions between *FTO* rs9939609 and *ABCA1* rs9282541 affecting BMI and WC was borderline significant (*P* = 0.054 and *P* = 0.063, respectively). This drop of significance is probably due to the lower sample size. Figure [2](#Fig2){ref-type="fig"} shows the mean proportion of Native American component according to *FTO* genotype, stratified by the absence or presence of the *ABCA1* risk allele ("CC" and "CT/TT" genotypes). As expected, the Native American component was lower in individuals with 1 and 2 FTO risk alleles, regardless of the presence of the ABCA1 risk allele. This suggests that the interactions are not confounded by ancestry.Fig. 2Mean Native American ancestry proportion according to FTO rs99399609 genotype, stratified by ABCA1 rs9282541 genotype in 2354 individuals

We sought to evaluate this finding in an independent cohort of 636 children. As observed in adults, in the overall analysis using an additive inheritance model, the association of *FTO* "A" and the *ABCA1* "T" risk alleles with BMI percentile did not reach statistical significance (β = 3.116, *P* = 0.084 and β = 4.002, *P* = 0.058, respectively). However, in the absence of the *ABCA1* "T" risk variant, the effect of *FTO* risk allele over the BMI was higher and significant (β = 4.20, *P* = 0.043, *n* = 505), although the interaction did not reach significance (*P* = 0.356).

We further explored whether *FTO* mRNA expression is affected by *ABCA1* genotypes. Figure [3](#Fig3){ref-type="fig"} shows differences in relative *FTO* mRNA expression levels in human adipose tissue biopsies according to *FTO* rs9939609 genotypes under a dominant model. In the overall analysis of SAT biopsies, while *FTO* mRNA expression was higher for "TA/AA" than those with "TT" genotypes, the difference did not reach statistical significance (9.084 vs 8.961 AU, respectively; *P* = 0.068). However, considering only biopsies of individuals not bearing the *ABCA1* risk allele (wild-type), *FTO* "TA/AA" SAT biopsies showed significantly higher *FTO* mRNA expression than those with "TT" genotypes (9.112 vs 8.943 AU, respectively; *P* = 0.003). Comparisons of *FTO* mRNA expression according to genotype in individuals bearing the *ABCA1* risk variant were limited because only one individual carried the *FTO* "TT" genotype. However, the *FTO* "TA/AA" SAT biopsies showed significantly lower *FTO* mRNA expression levels in the presence of the *ABCA*1 risk allele (9.043 vs 9.112, *P* = 0.045). In VAT biopsies, *FTO* mRNA expression did not differ significantly according to genotype in the overall population (TT: 8.879 vs TA/AA: 8.975, P = 0.857), or in absence of the R230C risk allele (TT: 8.942; TA/AA: 8.965, *P* = 0.371). *ABCA1* expression was not significantly affected by *FTO* rs9939609 genotypes (data not shown).Fig. 3*FTO* mRNA expression levels in subcutaneous (SAT) and visceral adipose tissue (VAT) biopsies, in all tested biopsies (*n* = 22), and in individuals not bearing the *ABCA1* rs9282541 risk variant (wild-type, *n* = 15). *P*-values were obtained adjusting by age and gender

Discussion {#Sec8}
==========

According to WHO, Mexico has one of the highest rates of adulthood and childhood obesity. This higher prevalence of obesity as compared to European populations could be explained by the Native American component as the result of adaptive processes related to energy saving, or could be the result ancestry-specific allele combinations derived from the admixture process. We thus analyzed whether the functional private *ABCA1*-R230C risk allele might interact with the most replicated obesity risk allele *FTO* rs9939609.

*FTO* and *ABCA1* risk allele frequencies were 20.3% y 10%, respectively, similar to previous reports \[[@CR2], [@CR3]\]. Individually, *FTO* and *ABCA1* risk alleles showed no significant association with BMI or WC. However, in the absence of the *ABCA1* risk variant, the effect of *FTO* on BMI and WC became stronger, statistically significant and similar to what has been reported in European populations \[[@CR9]\]. Observations from the cohort of children showed a similar trend, although the gene-gene interaction reached statistical significance only in the adult cohort. The lack of significance in children was likely due to the small sample size. Replication studies in independent adult and childhood cohorts are necessary to confirm this interaction. This type of interaction may explain differences in *FTO* associations with obesity between Mexican and European populations, but they do not explain the higher prevalence of obesity in Mexico.

*FTO* mRNA expression was significantly higher in SAT than in VAT, in accordance with previous studies in other populations \[[@CR10]\]. Interestingly, allele-specific *FTO* expression in SAT differed significantly only in the absence of the *ABCA1* risk allele, which is consistent with the interactions described above. It is noteworthy that no significant differences in allele-specific *FTO* expression have been observed in SAT biopsies from European individuals \[[@CR11], [@CR12]\]. However, a previous study in Mexican patients with morbid obesity, the rs9939609 "TA" genotype was significantly associated with higher *FTO* expression \[[@CR2]\]. Although the latter biopsies were not genotyped for *ABCA1-*R230C, it is noteworthy that the only independent studies reporting allele-specific differences were performed in Mexican patients.

Although *FTO* and *ABCA1* are both known to play a role in adipose tissue function, there is no previous experimental evidence directly linking the function of both genes \[[@CR13], [@CR14]\]. However, previous evidence supports the role of *ABCA1* in body fat distribution both in the Mexican population \[[@CR8]\], and in a recent multi-ethnic meta-analysis that identified *ABCA1* rs10991437 as a variant associated with higher waist-hip ratio adjusted for BMI \[[@CR15]\].

Conclusions {#Sec9}
===========

To our knowledge this is the first report showing evidence of FTO and ABCA1 gene variant interactions affecting BMI, which may explain previously reported population differences. Further studies are needed to understand the possible biological mechanisms underlying this interaction.
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ABCA1

:   ATP Binding cassette Transporter A-1

BMI

:   Body mass index

FTO

:   Fat mass and obesity associated gene

HDL-C

:   High Density Lipoprotein Cholesterol

WC

:   Waist circumference
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